Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$632.36

Earnings Summary

Revenue
$2857.2Mn
Net Profits
$852.1Mn
Net Profit Margins
29.82%
PE Ratio
12.83

Highlights

Revenue:

Regeneron Pharmaceuticals, Inc.’s revenue fell -44.4% since last year same period to $2857.2Mn in the Q2 2022. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -3.64% fall in its revenue since last 3-months.

Net Profits:

Regeneron Pharmaceuticals, Inc.’s net profit fell -72.5% since last year same period to $852.1Mn in the Q2 2022. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -12.47% fall in its net profits since last 3-months.

Net Profit Margins:

Regeneron Pharmaceuticals, Inc.’s net profit margin fell -50.55% since last year same period to 29.82% in the Q2 2022. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -9.16% fall in its net profit margins since last 3-months.

PE Ratio:

Regeneron Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q2 2022 earnings stands at 12.83.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Regeneron Pharmaceuticals, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
9.54
EPS Estimate Current Year
9.54

Highlights

EPS Estimate Current Quarter:

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 9.54 - a -2.85% fall from last quarter’s estimates.

EPS Estimate Current Year:

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 9.54.

Key Ratios

Key ratios of the Regeneron Pharmaceuticals, Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
9.77
Return on Assets (ROA)
0.18
Return on Equity (ROE)
0.32
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -65.07% since last year same period to 9.77 in the Q2 2022. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -65.07% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regeneron Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.32.

Dividend Per Share (DPS):

Regeneron Pharmaceuticals, Inc. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
9.82
11.49
17.01%
2022-06-30
9.54
9.77
2.41%

Company Information

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Organisation
Regeneron Pharmaceuticals, Inc.
Headquarters
Tarrytown, New York, United States
Employees
9.12K
Industry
Health Technology
CEO
Leonard Schleifer